JPWO2022073469A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022073469A5 JPWO2022073469A5 JP2023521512A JP2023521512A JPWO2022073469A5 JP WO2022073469 A5 JPWO2022073469 A5 JP WO2022073469A5 JP 2023521512 A JP2023521512 A JP 2023521512A JP 2023521512 A JP2023521512 A JP 2023521512A JP WO2022073469 A5 JPWO2022073469 A5 JP WO2022073469A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- dione
- dioxopiperidin
- isoindoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000004452 carbocyclyl group Chemical group 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims 2
- 229950006304 gilteritinib Drugs 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229950001845 lestaurtinib Drugs 0.000 claims 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 2
- 229950010895 midostaurin Drugs 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- TZUYPHOILWGNHN-FJHWNGQUSA-N CC(C)N1N=CC2=C1C=C(C1=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C1C1CC1)N=C2 Chemical compound CC(C)N1N=CC2=C1C=C(C1=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C1C1CC1)N=C2 TZUYPHOILWGNHN-FJHWNGQUSA-N 0.000 claims 1
- MZRSWFBICGMXJS-UHFFFAOYSA-N CC(N(CCCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N=C1C)=C1C1=NC2=CC=CC=C2N=C1 Chemical compound CC(N(CCCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N=C1C)=C1C1=NC2=CC=CC=C2N=C1 MZRSWFBICGMXJS-UHFFFAOYSA-N 0.000 claims 1
- SEOBFXVITPJXQT-FUHWPHGUSA-N CC(N=C(C=C1)C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C2CC2)=C1F Chemical compound CC(N=C(C=C1)C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C2CC2)=C1F SEOBFXVITPJXQT-FUHWPHGUSA-N 0.000 claims 1
- SRUYKCDYDRCNMN-SUBVVYJRSA-N CC1=CC=CC(C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C(F)F)=N1 Chemical compound CC1=CC=CC(C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C(F)F)=N1 SRUYKCDYDRCNMN-SUBVVYJRSA-N 0.000 claims 1
- WRCCZKNWIVEJRI-FPEFRKQASA-N CC1=CC=CC(C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C2CC2)=N1 Chemical compound CC1=CC=CC(C2=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C2C2CC2)=N1 WRCCZKNWIVEJRI-FPEFRKQASA-N 0.000 claims 1
- CRRJPYKKPKIFLM-JXVVUMDTSA-N CC1=CC=CN=C1C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 Chemical compound CC1=CC=CN=C1C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 CRRJPYKKPKIFLM-JXVVUMDTSA-N 0.000 claims 1
- XMOQXFVNMCQECH-JIZDIEQJSA-N CC1=NN([C@H]2C[C@H](CCCNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)C=C1C1=NC2=CC=CC(C3CCN(C)CC3)=C2N=C1 Chemical compound CC1=NN([C@H]2C[C@H](CCCNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)C=C1C1=NC2=CC=CC(C3CCN(C)CC3)=C2N=C1 XMOQXFVNMCQECH-JIZDIEQJSA-N 0.000 claims 1
- ZDEOJIHVRZZQSM-GXVNWILRSA-N CC1=NN([C@H]2C[C@H](CCCNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)C=C1C1=NC2=CC=CC=C2N=C1 Chemical compound CC1=NN([C@H]2C[C@H](CCCNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)C=C1C1=NC2=CC=CC=C2N=C1 ZDEOJIHVRZZQSM-GXVNWILRSA-N 0.000 claims 1
- GIOMHTOJGRMOKN-XTMLFJHRSA-N CN(CC1)CCN1C(C=C1N=C2)=CC=C1N=C2C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 Chemical compound CN(CC1)CCN1C(C=C1N=C2)=CC=C1N=C2C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 GIOMHTOJGRMOKN-XTMLFJHRSA-N 0.000 claims 1
- BKOVSNQJCYGHHM-UHFFFAOYSA-N CN(CC1)CCN1C1=CC=C2N=CC(C3=CN(CCCCCCNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)N=C3C3CC3)=NC2=C1 Chemical compound CN(CC1)CCN1C1=CC=C2N=CC(C3=CN(CCCCCCNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)N=C3C3CC3)=NC2=C1 BKOVSNQJCYGHHM-UHFFFAOYSA-N 0.000 claims 1
- JJVCAYAGWXZYGX-XUFQXJAUSA-N CN1N=CC2=C1C=C(C1=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C1C1CC1)N=C2 Chemical compound CN1N=CC2=C1C=C(C1=CN([C@H]3C[C@H](CNC(C=C4C(N5C(CCC(N6)=O)C6=O)=O)=CC=C4C5=O)C3)N=C1C1CC1)N=C2 JJVCAYAGWXZYGX-XUFQXJAUSA-N 0.000 claims 1
- DDWPJUHHNKZOIZ-WCVSPVLWSA-N COC1=CC=CN=C1C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 Chemical compound COC1=CC=CN=C1C1=CN([C@H]2C[C@H](CNC(C=C3C(N4C(CCC(N5)=O)C5=O)=O)=CC=C3C4=O)C2)N=C1C1CC1 DDWPJUHHNKZOIZ-WCVSPVLWSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- WDOSAZMVFYKEPG-UHFFFAOYSA-N O=C(C(C1=C2)=CC=C2NCCCC(C2)CC2N2N=CC(C3=NC4=CC(N5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCCC(C2)CC2N2N=CC(C3=NC4=CC(N5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O WDOSAZMVFYKEPG-UHFFFAOYSA-N 0.000 claims 1
- BDOIJQPNDMMRJW-UHFFFAOYSA-N O=C(C(C1=C2)=CC=C2NCCCCCCN2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCCCCCN2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O BDOIJQPNDMMRJW-UHFFFAOYSA-N 0.000 claims 1
- GZSSDMDUIZTGES-UHFFFAOYSA-N O=C(C(C1=C2)=CC=C2NCCCCCCN2N=CC(C(C=NC3=CC=C4)=NC3=C4Br)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCCCCCN2N=CC(C(C=NC3=CC=C4)=NC3=C4Br)=C2)N(C(CCC(N2)=O)C2=O)C1=O GZSSDMDUIZTGES-UHFFFAOYSA-N 0.000 claims 1
- JGXITGWKYJBDND-UHFFFAOYSA-N O=C(C(C1=C2)=CC=C2NCCCCCCN2N=CC(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCCCCCN2N=CC(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O JGXITGWKYJBDND-UHFFFAOYSA-N 0.000 claims 1
- JBQMJTAXTXQJKM-PRXVOJAISA-N O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=C(C(F)F)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=C(C(F)F)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O JBQMJTAXTXQJKM-PRXVOJAISA-N 0.000 claims 1
- YRHZUMCKISTTOI-RJIBILQUSA-N O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O YRHZUMCKISTTOI-RJIBILQUSA-N 0.000 claims 1
- HZLQUDUHBZFHFN-KDDNTLDISA-N O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=CC(C3=NC4=CC(C5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@@H]2N2N=CC(C3=NC4=CC(C5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O HZLQUDUHBZFHFN-KDDNTLDISA-N 0.000 claims 1
- VCEGUIPWALYWGE-BHVVZZKQSA-N O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@H]2N2N=C(C3CC3)C(C3=NC4=CC(N5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@H]2N2N=C(C3CC3)C(C3=NC4=CC(N5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O VCEGUIPWALYWGE-BHVVZZKQSA-N 0.000 claims 1
- HZLQUDUHBZFHFN-CFUPMNRXSA-N O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@H]2N2N=CC(C3=NC4=CC(C5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NCCC[C@H](C2)C[C@H]2N2N=CC(C3=NC4=CC(C5CCOCC5)=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O HZLQUDUHBZFHFN-CFUPMNRXSA-N 0.000 claims 1
- YRDAEXXGDFMHRC-LVUWARKWSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C(C=C3)=NC=C3Cl)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C(C=C3)=NC=C3Cl)=C2)N(C(CCC(N2)=O)C2=O)C1=O YRDAEXXGDFMHRC-LVUWARKWSA-N 0.000 claims 1
- QYZNQBVVSLSCEK-CXWZDPMFSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C(C=NC3=C4)=NC3=CC=C4N3CCOCC3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C(C=NC3=C4)=NC3=CC=C4N3CCOCC3)=C2)N(C(CCC(N2)=O)C2=O)C1=O QYZNQBVVSLSCEK-CXWZDPMFSA-N 0.000 claims 1
- DJKIXKIJDXLCKG-JAZIGOCYSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=C4N=CC=CC4=CC=N3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=C4N=CC=CC4=CC=N3)=C2)N(C(CCC(N2)=O)C2=O)C1=O DJKIXKIJDXLCKG-JAZIGOCYSA-N 0.000 claims 1
- IAEBVQNYKZSSCI-IVFRWPHNSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC4=CC=CC=C4N=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O IAEBVQNYKZSSCI-IVFRWPHNSA-N 0.000 claims 1
- KDHQOWSWYASLQS-LVUWARKWSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC(Cl)=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC(Cl)=C3)=C2)N(C(CCC(N2)=O)C2=O)C1=O KDHQOWSWYASLQS-LVUWARKWSA-N 0.000 claims 1
- FHVJWDZVOKLMGI-YHMAVIRVSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC4=NC=CN=C34)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC4=NC=CN=C34)=C2)N(C(CCC(N2)=O)C2=O)C1=O FHVJWDZVOKLMGI-YHMAVIRVSA-N 0.000 claims 1
- JILVYQAOHJCBBR-XZTDTORKSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC=C3Cl)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC=C3Cl)=C2)N(C(CCC(N2)=O)C2=O)C1=O JILVYQAOHJCBBR-XZTDTORKSA-N 0.000 claims 1
- VUHYBYOXDAQQJS-WAJZRPDGSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC=C3OC(F)(F)F)=C2)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C(C3=NC=CC=C3OC(F)(F)F)=C2)N(C(CCC(N2)=O)C2=O)C1=O VUHYBYOXDAQQJS-WAJZRPDGSA-N 0.000 claims 1
- IILXZGYRDBIOTJ-XZTDTORKSA-N O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C3=CC=CC=C23)N(C(CCC(N2)=O)C2=O)C1=O Chemical compound O=C(C(C1=C2)=CC=C2NC[C@H](C2)C[C@@H]2N2N=C(C3CC3)C3=CC=CC=C23)N(C(CCC(N2)=O)C2=O)C1=O IILXZGYRDBIOTJ-XZTDTORKSA-N 0.000 claims 1
- VDKLZKOEFDWKQD-UHFFFAOYSA-N O=C(C1=CC(CCCCCCCN2N=CC(C3=NC4=CC=CC=C4N=C3)=C2)=CC=C1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(C1=CC(CCCCCCCN2N=CC(C3=NC4=CC=CC=C4N=C3)=C2)=CC=C1C1)N1C(CCC(N1)=O)C1=O VDKLZKOEFDWKQD-UHFFFAOYSA-N 0.000 claims 1
- GQUMOYBJVVNSGS-UHFFFAOYSA-N O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1(C1=CC=CC=C1)F Chemical compound O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1(C1=CC=CC=C1)F GQUMOYBJVVNSGS-UHFFFAOYSA-N 0.000 claims 1
- WPQADJBPJPOUQI-UHFFFAOYSA-N O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1C(C=NC1=CC=C2)=NC1=C2Br Chemical compound O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1C(C=NC1=CC=C2)=NC1=C2Br WPQADJBPJPOUQI-UHFFFAOYSA-N 0.000 claims 1
- CGOSTRCSHPPBAF-UHFFFAOYSA-N O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1C1=CC(Cl)=CC=C1 Chemical compound O=C(CCCCCNC(C=C1C(N2C(CCC(N3)=O)C3=O)=O)=CC=C1C2=O)N(CC1)CCC1C1=CC(Cl)=CC=C1 CGOSTRCSHPPBAF-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/119834 | 2020-10-07 | ||
| CN2020119834 | 2020-10-07 | ||
| PCT/CN2021/122530 WO2022073469A1 (en) | 2020-10-07 | 2021-10-07 | Compounds and methods of treating cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545274A JP2023545274A (ja) | 2023-10-27 |
| JPWO2022073469A5 true JPWO2022073469A5 (https=) | 2024-10-16 |
| JP2023545274A5 JP2023545274A5 (https=) | 2024-10-16 |
Family
ID=81125595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521512A Pending JP2023545274A (ja) | 2020-10-07 | 2021-10-07 | 癌を処置する化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240050428A1 (https=) |
| EP (1) | EP4225749A4 (https=) |
| JP (1) | JP2023545274A (https=) |
| CN (1) | CN116583509A (https=) |
| WO (1) | WO2022073469A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| EP4353720A4 (en) * | 2021-10-01 | 2025-05-14 | Nextgen Bioscience Co., Ltd. | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING IT |
| US20250221988A1 (en) * | 2022-04-06 | 2025-07-10 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| US20250361239A1 (en) * | 2022-06-10 | 2025-11-27 | Zhuhai Yufan Biotechnologies Co., Ltd. | Protein degraders and uses thereof |
| WO2024015855A1 (en) * | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| EP4570792A1 (en) * | 2022-08-10 | 2025-06-18 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Compound based on isoindoline-substituted glutarimide backbone and use thereof |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| CN120303264A (zh) | 2022-09-09 | 2025-07-11 | 医诺康治疗公司 | CK1α和双重CK1α/GSPT1降解化合物 |
| WO2024099441A1 (en) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Bromodomain and extra-terminal (bet) protein degrader |
| JP2026500305A (ja) | 2022-12-16 | 2026-01-06 | アストラゼネカ・アクチエボラーグ | ２，６，９三置換プリン |
| JP2026511128A (ja) * | 2023-03-21 | 2026-04-10 | シャンハイ ヘリオソン ファーマシューティカル カンパニー リミテッド | イソインドリン誘導体、ベンゾインドール誘導体及びそれらの使用 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025231420A1 (en) * | 2024-05-03 | 2025-11-06 | Albert Einstein College Of Medicine | Small molecule degraders of soluble epoxide hydrolase |
| WO2026021557A1 (zh) * | 2024-07-26 | 2026-01-29 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| CN119059953A (zh) * | 2024-08-27 | 2024-12-03 | 吉林大学 | 一种快捷合成1-(乙基磺酰基)氮杂环丁烷-3-酮的方法 |
| WO2026061491A1 (zh) * | 2024-09-20 | 2026-03-26 | 上海超阳药业有限公司 | 一种苯并吲哚衍生物的晶型、盐型及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018011847A1 (ja) * | 2016-07-11 | 2018-01-18 | オリンパス株式会社 | 内視鏡処置具 |
| CA3043938A1 (en) * | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) * | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| EP4201399A3 (en) * | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN109422753B (zh) * | 2017-09-03 | 2021-12-31 | 上海美志医药科技有限公司 | 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物 |
| CN109912655B (zh) * | 2017-12-13 | 2021-12-10 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
| AU2019284608A1 (en) * | 2018-06-13 | 2020-12-17 | Biotheryx, Inc. | Aminoamide compounds |
| CN112601751B (zh) * | 2018-06-13 | 2024-04-02 | 拜欧斯瑞克斯公司 | 稠合噻吩化合物 |
| MX2021001957A (es) * | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| EP4041231A1 (en) * | 2019-10-09 | 2022-08-17 | Monte Rosa Therapeutics AG | Isoindolinone compounds |
-
2021
- 2021-10-07 CN CN202180082392.9A patent/CN116583509A/zh active Pending
- 2021-10-07 EP EP21876987.5A patent/EP4225749A4/en active Pending
- 2021-10-07 JP JP2023521512A patent/JP2023545274A/ja active Pending
- 2021-10-07 US US18/248,035 patent/US20240050428A1/en active Pending
- 2021-10-07 WO PCT/CN2021/122530 patent/WO2022073469A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022073469A5 (https=) | ||
| US10501456B2 (en) | Therapeutic agents for the treatment of HBV infection | |
| AU766081B2 (en) | Phthalazine derivatives for treating inflammatory diseases | |
| CN1960731B (zh) | 调节炎性和转移过程的方法 | |
| JP2016519096A5 (https=) | ||
| CN103124729B (zh) | 作为Axl抑制剂的药物活性化合物 | |
| KR101931468B1 (ko) | 아릴메톡시 이소인돌린 유도체 및 그를 포함하는 조성물 및 그의 사용 방법 | |
| JP5089377B2 (ja) | 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤 | |
| JP2006520805A5 (https=) | ||
| RU2003135424A (ru) | Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора | |
| CA2926478A1 (en) | Rho kinase inhibitors | |
| JP2002520323A (ja) | 抗ウイルス性大環状化合物 | |
| JP2016514718A5 (https=) | ||
| TW201429957A (zh) | 用於激酶調節及其適應症之化合物及方法 | |
| JP2018534328A5 (https=) | ||
| JPWO2019148044A5 (https=) | ||
| JP2004505964A (ja) | Ｖｅｇｆ阻害活性を有するキノリン誘導体 | |
| CN106132950A (zh) | 化合物和使用方法 | |
| CN121013856A (zh) | Egfr降解剂、其药物组合物及其用途 | |
| JPWO2021076688A5 (https=) | ||
| CA2629132C (en) | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis | |
| KR101276425B1 (ko) | 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 | |
| EP1843771A2 (en) | Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity | |
| WO2005075475A1 (ja) | Ｈｉｖインテグラーゼ阻害活性を有するナフチリジン誘導体 | |
| US20230365531A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumo virus |